A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)
Public ClinicalTrials.gov record NCT07421167. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Open-label Study to Evaluate the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least One Treatment (VAY2EXPLORE)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to investigate the tolerability of ianalumab (9 mg/kg) with investigator's choice thrombopoietin receptor agonist (IC TPO-RA) in participants diagnosed with primary immune thrombocytopenia (ITP) who have been treated with at least one but no more than four prior treatments, and with no change in IC TPO-RA dose in at least the last 14 days prior to the start of ianalumab.
Study identification
- NCT ID
- NCT07421167
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 164 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 4, 2026 (Actual)
- Primary completion
- Jan 18, 2029 (Estimated)
- Completion
- Aug 31, 2030 (Estimated)
- Last update posted
- Oct 15, 2026
2026 – 2030
United States locations
- U.S. sites
- 18
- U.S. states
- 14
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Highlands Oncology Group | Fayetteville | Arkansas | 72703 | Recruiting |
| Harbor-UCLA Medical Center | Torrance | California | 90502 | Recruiting |
| Yale Cancer Center | New Haven | Connecticut | 06520 | Recruiting |
| Stamford Hospital | Stamford | Connecticut | 06902 | Recruiting |
| Baptist MD Anderson Cancer Center | Jacksonville | Florida | 32207 | Recruiting |
| DH Cancer Research Center LLC | Margate | Florida | 33063 | Recruiting |
| University Of Miami | Miami | Florida | 33136 | Recruiting |
| Hope And Healing Care | Hinsdale | Illinois | 60521 | Recruiting |
| Pontchartrain Cancer Center | Covington | Louisiana | 70433 | Recruiting |
| Mayo Clinic Rochester | Rochester | Minnesota | 55905 | Recruiting |
| University Health Kansas City | Kansas City | Missouri | 64108 | Recruiting |
| Intermountain Healthcare | Billings | Montana | 59102 | Recruiting |
| Astera Cancer Center | East Brunswick | New Jersey | 08816 | Recruiting |
| Summit Medical Group | Summit | New Jersey | 07901 | Recruiting |
| Montefiore Medical Center | The Bronx | New York | 10467 | Recruiting |
| Western Pennsylvania Hospital | Pittsburgh | Pennsylvania | 15224 | Recruiting |
| Avera Cancer Institute | Sioux Falls | South Dakota | 57106 | Recruiting |
| Utah Cancer Specialists | Salt Lake City | Utah | 84106 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07421167, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 15, 2026 · Synced Oct 16, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT07421167 live on ClinicalTrials.gov.